The use of IVUS remains low despite growing clinical evidence and increasing inclusion in practice guidelines.
The document, published simultaneously in the
The panel looks forward to working with our collective societies to increase access to training with IVUS, support strong reimbursement to allow for wider adoption, and work to incorporate IVUS into clinical guidelines.
Lead author
Peripheral arterial disease (PAD) and deep venous disease effect nearly 200 million people worldwide, including approximately 40 to 45 million Americans [4]. Minimally invasive treatments for peripheral vascular disease (PVD) are increasingly common, but traditional imaging techniques like angiography have limitations, including 2-dimensional projections of 3-dimensional vasculature, which can complicate diagnosis and intraprocedural optimization.
Significant value for procedural staff and patients
Published today as 'Intravascular Ultrasound Use in Peripheral arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS,' the panel acknowledged that IVUS utilization remains low despite growing data and clinical experience demonstrating benefits of IVUS in contemporary peripheral interventions. Compared with angiography alone, the document highlights advantages of IVUS including identification of plaque burden and morphology, lesion characteristics as well as stent sizing and positioning which translate into improvements in procedural safety and long-term patient outcomes.
There was agreement among experts that the main evidence gap for peripheral arterial use was determining if uptake in practice can improve procedural success. Importantly, the authors also noted that the reductions in radiation exposure in an IVUS-guided procedure has significant value for both operative staff and patients that may on its own be sufficient to justify use. Besides positive impact on radiation safety and patient contrast load, IVUS may also play an important role in the use in novel technologies, like ultrasound renal denervation - a minimally invasive therapy option for the treatment of uncontrolled hypertension [5] involving the use of ultrasound energy to treat overactive renal nerves, which can help lower high blood pressure [5,6].
The committee also identified several barriers to increased IVUS use including limitations with access to technology and training, restrictive reimbursement and perceptions around added time. The joint multidisciplinary expert opinion is timed to recent policy proposals by
Using a miniaturized ultrasound transducer mounted on the tip of a catheter, IVUS captures real-time images inside the vessel. IVUS imaging enables physicians to formulate patient-specific treatment plans. Philips is the global leader in IVUS solutions.
Presentation
Multidisciplinary expert opinion will be presented at the International Symposium of Endovascular Therapies (ISET) annual meeting on
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in
Contact:
Joost Maltha
Tel: +31 6 10 55 8116
(C) 2024 Electronic News Publishing, source